-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $26

Benzinga·02/25/2026 15:12:09
Listen to the news
RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and raises the price target from $22 to $26.